| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 60687-0876-65 | 60687-0876 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | May 2, 2025 | In Use | ||
| 75834-0146-05 | 75834-0146 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec 7, 2021 | In Use | |
| 59572-0730-14 | 59572-0730 | azacitidine | ONUREG | 200.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Sep 1, 2020 | In Use | |
| 73190-0034-12 | 73190-0034 | Nilotinib | Nilotinib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 2, 2026 | In Use | |
| 33261-0740-28 | 33261-0740 | Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 5.0 mg/1 | Hormonal Therapy | Progestin | Oral | Dec 3, 1996 | In Use | ||
| 00078-0671-19 | 00078-0671 | Lapatinib | TYKERB | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Aug 3, 2016 | In Use | |
| 70377-0052-12 | 70377-0052 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2025 | In Use | |
| 63323-0126-00 | 63323-0126 | GEMCITABINE | GEMCITABINE | 2.0 g/50mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 17, 2011 | In Use | |
| 25021-0251-50 | 25021-0251 | Mitomycin | Mitomycin | 20.0 mg/40mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Jun 15, 2023 | In Use | |
| 00143-9202-01 | 00143-9202 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug 7, 2007 | In Use | |
| 00591-4390-96 | 00591-4390 | Mifepristone | Mifepristone | 300.0 mg/1 | Hormonal Therapy | Antiprogestin | Cortisol Receptor Blocker | Oral | Jan 19, 2024 | In Use | |
| 68001-0667-01 | 68001-0667 | Aprepitant | Aprepitant | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Feb 2, 2026 | In Use | |
| 76282-0696-48 | 76282-0696 | LENALIDOMIDE | LENALIDOMIDE | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jun 10, 2024 | In Use | |
| 50242-0061-01 | 50242-0061 | Bevacizumab | Avastin | 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Feb 26, 2004 | In Use | |
| 69448-0025-63 | 69448-0025 | Pegfilgrastim-cbqv | UDENYCA | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Dec 15, 2025 | In Use | |
| 55111-0154-30 | 55111-0154 | Ondansetron Hydrochloride | ONDANSETRON | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 26, 2006 | In Use | |
| 70518-4524-04 | 70518-4524 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 9, 2026 | In Use | |
| 50090-5814-03 | 50090-5814 | PREDNISONE | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 18, 2021 | In Use | |
| 25021-0233-10 | 25021-0233 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sep 15, 2014 | In Use | |
| 60687-0112-21 | 60687-0112 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Feb 3, 2016 | In Use | ||
| 55513-0126-10 | 55513-0126 | Epoetin alfa | Epogen | 2000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 30, 1989 | In Use | ||
| 25021-0826-67 | 25021-0826 | Zoledronic Acid | Zoledronic Acid | 0.04 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Sep 1, 2015 | In Use | ||
| 00006-3066-01 | 00006-3066 | Aprepitant | Emend | 125.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec 17, 2015 | In Use | |
| 23155-0875-03 | 23155-0875 | Letrozole Tablets | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jun 1, 2023 | In Use | ||
| 55150-0354-01 | 55150-0354 | IRINOTECAN HYDROCHLORIDE | IRINOTECAN HYDROCHLORIDE | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb 11, 2020 | In Use |
Found 12611 results — Export these results
Home